<DOC>
	<DOCNO>NCT00415285</DOCNO>
	<brief_summary>The purpose study identify new chemotherapy treatment regimens good response rate find combination docetaxel capecitabine shrink size breast tumor preserve breast .</brief_summary>
	<brief_title>Docetaxel Followed Capecitabine Versus Concomitant Docetaxel/Capecitabine Early Stage Breast Cancer</brief_title>
	<detailed_description>The purpose study identify new chemotherapy treatment regimens good response rate find combination docetaxel capecitabine shrink size breast tumor preserve breast . Induction chemotherapy offer possibility le surgery determines tumor sensitivity vivo . Previous trial demonstrate complete pathologic response breast surgery correspond improved outcome . Additionally , correlate specific molecular marker breast tumor chemotherapy , response treatment . Expression molecular market may use future predict likelihood response chemotherapy give post-operatively . Approximately 100 patient participate Emory Winship Cancer Institute Emory Crawford W. Long Hospital Grady Health System Atlanta , Georgia .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm breast carcinoma . Early stage breast cancer ( stage 1 , 2 , 3 ) . No evidence disease outside breast chest wall , except ipsilateral axillary lymph node . 18 year age old . Final eligibility clinical trial determine health professional conduct trial . Prior chemotherapy , hormonal therapy , biologic therapy radiation therapy breast cancer . Major surgery within 28 day study entry . Evidence CNS metastasis . Final eligibility clinical trial determine health professional conduct trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
	<keyword>Early-Stage</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>